Passage Bio Stock Investor Sentiment
| PASG Stock | USD 5.56 0.21 3.64% |
Roughly 67% of Passage Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding Passage Bio suggests that many traders are alarmed. The current market sentiment, together with Passage Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use Passage Bio stock news signals to limit their universe of possible portfolio assets.
Passage Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Passage Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Passage Bio's Stock prices. Below is the latest headlines and news related to Passage Bio Stock. Current markets are slightly bullish. About 55% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Passage Bio that are available to investors today. This information is accessible both publicly - through Passage Bio's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Passage-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Passage Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Passage Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Passage Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Passage Bio alpha.
Passage Largest EPS Surprises
Earnings surprises can significantly impact Passage Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-05-12 | 2025-03-31 | -0.2233 | -0.25 | -0.0267 | 11 | ||
2024-08-08 | 2024-06-30 | -0.31 | -0.26 | 0.05 | 16 | ||
2024-05-14 | 2024-03-31 | -0.36 | -0.3 | 0.06 | 16 | ||
2024-03-04 | 2023-12-31 | -0.4 | -0.3 | 0.1 | 25 | ||
2022-08-04 | 2022-06-30 | -0.83 | -0.73 | 0.1 | 12 | ||
2022-05-16 | 2022-03-31 | -0.89 | -0.79 | 0.1 | 11 |
There is far too much social signal, news, headlines, and media speculation about Passage Bio that are available to investors today. This information is accessible both publicly - through Passage Bio's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Passage-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Passage Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Passage Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Passage Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Passage Bio alpha.
Passage Bio Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 89328 shares by Orbimed Advisors Llc of Passage Bio at 0.34 subject to Rule 16b-3 | 04/23/2025 |
2 | Disposition of 68195 shares by Orbimed Advisors Llc of Passage Bio at 0.32 subject to Rule 16b-3 | 04/24/2025 |
3 | Passage Bio Advances Phase 12 Trial for PBFT02, Eyes Future Milestones PASG Stock News | 05/13/2025 |
4 | Guggenheim Adjusts Price Target for Passage Bio PASG Stock News | 05/20/2025 |
5 | Acquisition by Kassberg Thomas Richard of 143789 shares of Passage Bio at 0.3598 subject to Rule 16b-3 | 05/28/2025 |
6 | Passage Bio Announces Key Updates from PBFT02 Clinical Trial PASG Stock News | 06/23/2025 |
7 | Disposition of 231600 shares by Orbimed Advisors Llc of Passage Bio at 0.35 subject to Rule 16b-3 | 06/24/2025 |
8 | Disposition of 213257 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3 | 06/26/2025 |
9 | Passage Bio Announces 1-for-20 Reverse Stock Split PASG Stock News | 07/10/2025 |
10 | Is Passage Bio Inc. a good long term investment - Tremendous portfolio expansion - Jammu Links News | 07/18/2025 |
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |